<!DOCTYPE article SYSTEM "../../../../Ncbi/ArchivingDTD/DTD/Working/archivearticle.dtd">
<article>
<front>
<?mtl hellip?>
<!-- Reflist, citation , and a reference -->
<journal-meta><journal-id journal-id-type="pmc">jcm</journal-id><journal-id journal-id-type="pubmed">J
Clin Microbiol</journal-id><journal-id journal-id-type="publisher">J CLIN
MICROBIOL</journal-id><issn>0095-1137</issn><publisher><publisher-name>American Society for
Microbiology</publisher-name></publisher></journal-meta><article-meta><article-id
pub-id-type="publisher-id">0064</article-id><article-id
pub-id-type="doi">10.1128/JCM.39.7.2729-2731.2001</article-id><article-id
pub-id-type="pmid">11427608</article-id>
<article-categories><subj-group><subject>Bacteriology</subject></subj-group><series-title>
Note</series-title></article-categories><title-group><article-title>Comparative Evaluation of
Penicillin, Ampicillin, and Imipenem MICs and Susceptibility Breakpoints for
Vancomycin-Susceptible and Vancomycin-Resistant <italic>Enterococcus faecalis</italic>
and <italic>Enterococcus faecium</italic></article-title></title-group><contrib-group><contrib
contrib-type="author"><name><surname>Weinstein</surname><given-names>Melvin
P.</given-names></name><xref ref-type="author-notes"
rid="FN150">&#x002A;</xref></contrib></contrib-group><aff>Departments of Medicine
and Pathology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New
Jersey 08901-0019</aff><author-notes><fn id="FN150" symbol="&#x002A;"><p>Mailing
address: Departments of Medicine and Pathology, UMDNJ-Robert Wood Johnson
Medical School, 1 Robert Wood Johnson Pl., New Brunswick, NJ 08901-0019. Phone:
(732) 235-7713. Fax: (732) 235-7951. E-mail:
<email>weinstei@umdnj.edu</email>.</p></fn></author-notes><pub-date
pub-type="pub"><day>1</day><month>7</month><year>2001</year></pub-date><volume>39
</volume><issue>7</issue><fpage>2729</fpage><lpage>2731</lpage><history><date
date-type="received"><day>19</day><month>1</month><year>2001</year></date><date
date-type="rev-request"><day>28</day><month>3</month><year>2001</year></date>
<date
date-type="accepted"><day>3</day><month>5</month><year>2001</year></date>
</history><copyright-statement>Copyright &#x00A9; 2001, American Society for
Microbiology</copyright-statement><abstract><p>Although imipenem has in vitro activity against
<italic>Enterococcus faecalis</italic> and Food and Drug Administration-approved
indications for treatment of infections caused by this microorganism, there are
no NCCLS guidelines for susceptibility testing of imipenem versus enterococci.
Therefore, the in vitro activities of penicillin, ampicillin, imipenem, and
vancomycin against 201 blood isolates of <italic>E. faecalis</italic> and 24 blood
isolates of <italic>Enterococcus faecium</italic> were compared. The susceptibility of
isolates to penicillin or ampicillin accurately predicted the in vitro activity
of imipenem. Since the susceptibility of enterococci to imipenem can be
predicted by the results obtained by testing of penicillin or ampicillin,
testing of imipenem by clinical laboratories probably is not
necessary.</p></abstract></article-meta><?mtl /hellip?></front>
<body><?mtl hellip?><p>Imipenem, the first widely used carbapenem antimicrobial
agent, was shown in early studies to have good in vitro activity against
<italic>Enterococcus faecalis</italic> (<xref ref-type="bibr" rid="B1">1</xref>, <xref
ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>,
<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr"
rid="B10">10</xref>) but little activity against <italic>Enterococcus faecium</italic>
(<xref ref-type="bibr" rid="B2">2</xref>). However, present NCCLS-approved
standards for in vitro susceptibility testing (<xref ref-type="bibr"
rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>) provide no guidance
for testing imipenem versus enterococci, nor are there statements that in vitro
susceptibility results for other antimicrobial agents can predict the in vitro
activity of imipenem against these bacteria. Nevertheless, clinicians and
microbiologists attending a recent meeting of the NCCLS Subcommittee on
Antimicrobial Susceptibility Testing (June 1999) agreed that penicillin and/or
ampicillin treatment likely would predict the activity of imipenem (M. P.
Weinstein, personal observation). In the absence of systematically gathered and
published data, however, the question remains open. Therefore, 225 isolates from
patients with enterococcal bacteremia were tested against imipenem, penicillin,
ampicillin, and vancomycin to determine the in vitro activity of each agent as
well as the degree to which each drug predicted the in vitro activity of
imipenem.</p><p>Enterococcal isolates causing bacteremia in patients
hospitalized at Robert Wood Johnson University Hospital from July 1997 through
October 1999 were tested. These included 201 <italic>E. faecalis</italic> (24
vancomycin-resistant) and 24 <italic>E. faecium</italic> (19 vancomycin-resistant)
isolates. All isolates were identified in the Robert Wood Johnson University
Hospital Clinical Microbiology Laboratory using dried-overnight (conventional)
gram-positive combination panels in the MicroScan WalkAway 96 Instrument (Dade
MicroScan, Inc., West Sacramento, Calif.). Species identification of strains
with unusual susceptibility patterns (e.g., vancomycin-intermediate <italic>E.
faecalis</italic> and ampicillin-susceptible <italic>E. faecium</italic>) was confirmed by
conventional microbiological testing (<xref ref-type="bibr" rid="B3">3</xref>).
Prior to testing, isolates were thawed and subcultured twice to ensure purity
and viability.</p><p>Each isolate was tested versus penicillin, ampicillin,
imipenem, and vancomycin. Solutions of all antimicrobials were prepared from
standard powders of known potencies obtained either from the manufacturer of the
compound or from a commercial source (Sigma, St. Louis, Mo.). MICs were
determined in duplicate by the microdilution method of the NCCLS using
cation-adjusted Mueller-Hinton broth (<xref ref-type="bibr"
rid="B7">7</xref>).</p><p>Of the 201 <italic>E. faecalis</italic> strains tested, 175
were susceptible to vancomycin (MIC &#x2264; 4 &#x03BC;g/ml), 2 were
intermediate (MIC = 8 &#x03BC;g/ml for both strains), and 24 were resistant (MIC
&#x2265; 32 &#x03BC;g/ml). The MIC ranges, MICs at which 50&#x0025; of the
isolates tested were inhibited (MIC<sub>50</sub>s), and MIC<sub>90</sub>s of
penicillin, ampicillin, and imipenem were comparable for vancomycin-susceptible
and vancomycin-resistant isolates (Table <xref ref-type="table"
rid="T1">1</xref>). The MIC<sub>90</sub>s of all three agents were in the
susceptible range even for the vancomycin-resistant isolates. Of the 24 <italic>E.
faecium</italic> strains tested, 5 were susceptible to vancomycin and 19 were
resistant to vancomycin. The penicillin, ampicillin, and imipenem MIC ranges for
the five vancomycin-susceptible strains are shown in Table <xref ref-type="table"
rid="T1">1</xref>. Two of the five strains were susceptible to penicillin and
ampicillin, whereas MICs for three strains were of &#x2265;64 &#x03BC;g/ml. For
the 19 vancomycin-resistant strains, MIC ranges and MIC<sub>50</sub>s and
MIC<sub>90</sub>s of all three antimicrobials were &#x003E;64 &#x03BC;g/ml
(Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1"><label>Table
1</label><caption><p>Susceptibility of vancomycin-susceptible and
vancomycin-resistant enterococci to penicillin, ampicillin, and imipenem<xref
ref-type="table-fn" rid="TF1-A"></xref></p></caption><table><tr><th>Microorganism
(<italic>n</italic>)</th><th>Antimicrobial agent</th><th>MIC range
(&#x03BC;g/ml)</th><th>MIC<sub>50</sub> (&#x03BC;g/ml)</th><th>MIC<sub>90</sub>
(&#x03BC;g/ml)</th></tr><tr><td
colspan="5"><hr/></td></tr><tr><td>Vancomycin-susceptible <italic>E. faecalis</italic>
(175)</td><td
align="left">Penicillin</td><td>0.5&#x2013;16</td><td>4</td><td>4</td></tr><tr>
<td/><td
align="left">Ampicillin</td><td>0.25&#x2013;4</td><td>1</td><td>2</td></tr><tr>
<td/><td align="left">Imipenem</td><td>0.06&#x2013;4</td><td>1</td><td>2
</td></tr><tr><td>Vancomycin-resistant <italic>E. faecalis</italic> (24)</td>
<td align="left">Penicillin</td>
<td>2&#x2013;4</td>
<td>4</td>
<td>4</td></tr>
<tr><td/>
<td
align="left">Ampicillin</td><td>0.5&#x2013;4</td><td>1</td><td>2</td></tr><tr>
<td/><td align="left">Imipenem</td><td>0.5&#x2013;2</td><td>1</td><td>2
</td></tr><tr><td>Vancomycin-susceptible <italic>E. faecium</italic> (5)</td><td
align="left">Penicillin</td><td>2&#x2013;&#x003E;64</td><td/><td/></tr><tr><td/>
<td
align="left">Ampicillin</td><td>1&#x2013;&#x003E;64</td><td/><td/></tr><tr><td/>
<td
align="left">Imipenem</td><td>0.5&#x2013;&#x003E;64</td><td/><td/></tr><tr><td>
Vancomycin-resistant <italic>E. faecium</italic> (19)</td><td
align="left">Penicillin</td><td>&#x003E;64</td><td>&#x003E;64</td><td>&#x003E;64
</td></tr><tr><td/><td
align="left">Ampicillin</td><td>&#x2265;64</td><td>&#x003E;64</td><td>&#x003E;64
</td></tr><tr><td/><td
align="left">Imipenem</td><td>&#x2265;64</td><td>&#x003E;64</td><td>&#x003E;64
</td></tr></table><table-wrap-foot><fn id="TF1-A"><p>Two <italic>E. faecalis</italic> strains were
intermediately susceptible to vancomycin (MIC = 8 &#x03BC;g/ml). Empty cells
indicate that the MIC<sub>50</sub> and MIC<sub>90</sub> were not calculated
(<italic>n</italic> &#x003C; 10).</p></fn></table-wrap-foot></table-wrap><p>Using the present published
NCCLS breakpoints for penicillin and ampicillin versus enterococci (<xref
ref-type="bibr" rid="B7">7</xref>) (susceptible, &#x2264;8 &#x03BC;g/ml;
resistant, &#x2265;16 &#x03BC;g/ml) and the breakpoints for imipenem published
in the manufacturer's package insert approved by the Food and Drug
Administration (FDA) (susceptible, &#x2264; 4 &#x03BC;g/ml; intermediate, 8
&#x03BC;g/ml; resistant, &#x2265;16 &#x03BC;g/ml), the ability of penicillin and
ampicillin MICs to predict in vitro susceptibility of enterococci versus
imipenem was assessed. As shown in Table <xref ref-type="table" rid="T2">2</xref>,
of the 201 <italic>E. faecalis</italic> strains tested, penicillin results correctly
predicted imipenem results for 200 (99.5&#x0025;) strains, and ampicillin
results correctly predicted the results for imipenem for all 201 strains. For
the 24 <italic>E. faecium</italic> strains, the results for penicillin and ampicillin
were identical. Of two penicillin- and ampicillin-susceptible strains, one was
susceptible to imipenem and one was intermediate (Table <xref ref-type="table"
rid="T2">2</xref>). All 22 strains that were resistant to penicillin and
ampicillin were also resistant to imipenem.</p><table-wrap id="T2"><label>Table
2</label><caption><p>Correlation of penicillin and ampicillin NCCLS
susceptibility breakpoints for enterococci with imipenem FDA susceptibility
breakpoints<xref ref-type="table-fn"
rid="TF2-A"></xref></p></caption><table><tr><th rowspan="3">Strain<xref
ref-type="table-fn" rid="TF2-B"></xref></th><th rowspan="3">Breakpoint for
penicillin or ampicillin (&#x03BC;g/ml)</th><th colspan="3">No. of strains
correlating with imipenem breakpoint (&#x03BC;g/ml) </th></tr><tr><td
colspan="3"><hr/></td></tr><tr><th>&#x2264;4</th><th>8</th><th>&#x2265;16
</th></tr><tr><td colspan="5"><hr/></td></tr><tr><td><italic>E.
faecalis</italic></td><td>Penicillin (&#x2264;8)</td><td>200</td><td>0</td><td>0
</td></tr><tr><td/><td>Penicillin
(&#x2265;16)</td><td>1</td><td>0</td><td>0</td></tr><tr><td/><td>Ampicillin
(&#x2264;8)</td><td>201</td><td>0</td><td>0 </td></tr><tr><td/><td>Ampicillin
(&#x2265;16)</td><td>0</td><td>0</td><td>0 </td></tr><tr><td><italic>E.
faecium</italic></td><td>Penicillin (&#x2264;8)</td><td>1</td><td>1</td><td>0
</td></tr><tr><td/><td>Penicillin
(&#x2265;16)</td><td>0</td><td>0</td><td>22</td></tr><tr><td/><td>Ampicillin
(&#x2264;8)</td><td>1</td><td>1</td><td>0 </td></tr><tr><td/><td>Ampicillin
(&#x2265;16)</td><td>0</td><td>0</td><td>22</td></tr></table><table-wrap-foot><fn
id="TF2-A"><p>NCCLS breakpoints (in micrograms per milliliter) for penicillin
and ampicillin: &#x2264;8, susceptible; &#x2265;16, resistant. FDA breakpoints
(in micrograms per milliliter) for imipenem: &#x2264;4, susceptible; 8,
intermediate; &#x2265;16, resistant.</p></fn><fn id="TF2-B"><p>For <italic>E.
faecalis</italic>, <italic>n</italic> = 201, including 24 vancomycin-resistant strains. For
<italic>E. faecium</italic>, <italic>n</italic> = 24, including 19 vancomycin-resistant
strains.</p></fn></table-wrap-foot></table-wrap><p>The results of this study confirm the widely
held but poorly documented belief that the in vitro activity of penicillin and
ampicillin versus <italic>E. faecalis</italic> and <italic>E. faecium</italic> accurately
predicts that of imipenem. The importance of this information lies in the fact
that enterococci often are potential pathogens of mixed infections for which a
broad-spectrum antimicrobial agent such as imipenem has a therapeutic role.
Imipenem currently has FDA indications for use in intra-abdominal infections,
skin and skin structure infections, and gynecologic infections caused by <italic>E.
faecalis</italic> but not by <italic>E. faecium</italic>. The drug also is used in some
institutions as monotherapy for patients with neutropenic
fever.</p><p>Presently, there are no NCCLS susceptibility testing guidelines for
imipenem against enterococci (<xref ref-type="bibr" rid="B6">6</xref>, <xref
ref-type="bibr" rid="B7">7</xref>) and, based on the data from this study,
specific testing guidelines for imipenem do not appear to be needed. However,
several limitations of the data make firm conclusions from this report
problematic. First, all of the microorganisms tested came from a single
institution. Second, a relatively small number of <italic>E. faecium</italic> strains
were tested. Although it is possible that these strains might represent only a
few clones, prior work from our institution has shown our <italic>E. faecium</italic>
strains to be polyclonal (H. Soliman, K. L. Joho, K. Damerau, R. Kuk, M. P.
Weinstein, and J. F. John, Abstr. 93rd Gen. Meet. Am. Soc. Microbiol. 1993,
abstr. A-80, p. 15, 1993). Third, no species other than <italic>E. faecalis</italic> and
<italic>E. faecium</italic> were included.</p><p>To address these limitations, it will
be necessary to study additional <italic>E. faecalis</italic> and <italic>E. faecium</italic>
strains from other geographic regions and, if possible, to include less common
enterococcal species, such as <italic>Enterococcus gallinarum, Enterococcus
casseliflavus, Enterococcus raffinosus,</italic> and <italic>Enterococcus avium</italic>,
thereby meeting the suggested criteria of the NCCLS (<xref ref-type="bibr"
rid="B8">8</xref>). If the initial results from the present study are confirmed,
microbiology laboratories and clinicians will benefit from a therapeutic note in
the NCCLS guidelines and tables indicating that the in vitro results obtained
for penicillin or ampicillin will accurately predict the in vitro susceptibility
of imipenem.</p><?mtl /hellip?></body>
<back><?mtl hellip?><ack><p>This study was supported
in part by Merck &#x0026; Co., Inc.</p><p>I thank James H. Jorgensen for review
of the manuscript and Judy Rothberg for technical
assistance.</p></ack><?mtl /hellip?>
<ref-list>
<title>REFERENCES</title>
<?mtl hellip?><ref id="B1"><label>1</label><citation>
<name><surname>Cohn</surname><given-names>D.L.</given-names></name>
<name><surname>Reimer</surname><given-names>L.G.</given-names></name>
<name><surname>Reller</surname><given-names>L.B.</given-names></name>
<article-title>Comparative in-vitro activity of MK0787
(<italic>N</italic>-formimidoyl thienamycin) against 540 blood culture
isolates.</article-title>
<source>J. Antimicrob. Chemother.</source>
<volume>9</volume><year>1982</year><fpage>183</fpage><lpage>194</lpage>.
<pub-id pub-id-type="pmid">6210653</pub-id> 
</citation></ref>
<ref id="B2"><label>2</label><citation>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names>
<suffix>Jr.</suffix></name>
<article-title>Susceptibility of enterococci and <italic>Listeria 
monocytogenes</italic> to <italic>N</italic>-formimidoyl thienamycin alone 
and in combination with an aminoglycoside.</article-title>
<source>Antimicrob. Agents Chemother.</source>
<volume>19</volume><year>1981</year><fpage>789</fpage><lpage>793</lpage>.
<pub-id pub-id-type="pmid">6794445</pub-id> </citation></ref>

<ref id="B3"><label>3</label><citation>
<name><surname>Facklam</surname><given-names>R. R.</given-names></name>
<name><surname>Sahm</surname><given-names>D. F.</given-names></name>
<name><surname>Teixeira</surname><given-names>L. M.</given-names></name>
<article-title>Enterococcus</article-title>
<source>Manual of clinical microbiology</source>
<edition>7th ed.</edition>
<name><surname>Murray</surname><given-names>P. R.</given-names></name>
<name><surname>Baron</surname><given-names>E. J.</given-names></name>
<name><surname>Pfaller</surname><given-names>M. A.</given-names></name>
<name><surname>Tenover</surname><given-names>F. C.</given-names>
</name><name><surname>Yolken</surname><given-names>R. H.</given-names></name>
<year>1999</year><fpage>297</fpage><lpage>305</lpage>
<publisher-name>American Society for Microbiology</publisher-name>
<publisher-loc>Washington, D.C.</publisher-loc></citation></ref>

<ref id="B4"><label>4</label><citation><name><surname>Horadam</surname>
<given-names>V.W.</given-names></name>
<name><surname>Smilack</surname><given-names>J.D.</given-names></name>
<name><surname>Montgomery</surname><given-names>C.L.</given-names></name>
<name><surname>Werringloer</surname><given-names>J.</given-names></name>
<article-title>In vitro activity of <italic>N</italic>-formimidoyl 
thienamycin (MK0787), a crystalline derivative of thienamycin.</article-title>
<source>Antimicrob. Agents Chemother.</source>
<volume>18</volume><year>1980</year><fpage>557</fpage><lpage> 561</lpage>.
<pub-id pub-id-type="pmid">6934707</pub-id> 
</citation></ref>
<ref id="B5"><label>5</label><citation>
<name><surname>Kropp</surname><given-names>H.</given-names></name>
<name><surname>Gerckens</surname><given-names>L.</given-names></name>
<name><surname>Sundelof</surname><given-names>J.G.</given-names></name>
<name><surname>Kahan</surname><given-names>F.M.</given-names></name>
<article-title>Antibacterial activity of imipenem: the first
thienamycin antibiotic.</article-title>
<source>Rev. Infect. Dis.</source><volume>7(Suppl.)</volume>
<year>1985</year><fpage>S411</fpage><lpage>S416</lpage>.
</citation></ref>
<?mtl /hellip?>
<ref id="B6"><label>6</label>
<citation>
<collab>National Committee for Clinical Laboratory 
Standards</collab>
<source>Performance standards for antimicrobial disk 
susceptibility tests. Approved standard</source>
<edition>7th ed.</edition>
<year>2000</year>
<fpage>M2</fpage>
<lpage>A7</lpage>
<publisher-name>National Committee for Clinical 
Laboratory Standards</publisher-name>
<publisher-loc>Wayne, Pa</publisher-loc>.</citation>
</ref>
<?mtl hellip?>
<ref id="B7"><label>7</label><citation><collab>National Committee for Clinical
Laboratory Standards</collab><source>Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically. Approved
standard</source><edition>5th
ed.</edition><year>2000</year><fpage>M7</fpage><lpage>A-5</lpage><publisher-name>
National Committee for Clinical Laboratory Standards</publisher-name><publisher-loc>Wayne,
Pa</publisher-loc>.</citation></ref><ref
id="B8"><label>8</label><citation><collab>National Committee for Clinical
Laboratory Standards</collab><source>Development of <italic>in vitro</italic>
susceptibility testing criteria and quality control parameters. Tentative
guideline</source><edition>3rd
ed.</edition><year>1998</year><fpage>M23</fpage><lpage>T3</lpage><publisher-name>
National Committee for Clinical Laboratory Standards</publisher-name><publisher-loc>Wayne,
Pa</publisher-loc>.</citation></ref><ref
id="B9"><label>9</label><citation><name><surname>Neu</surname><given-names>H.
C.</given-names></name><name><surname>Labthavikul</surname><given-names>P.</given-names></name><article-title>
Comparative in vitro activity of <italic>N</italic>-formimidoyl thienamycin against
gram-positive and gram-negative aerobic and anaerobic species and its
&#x03B2;-lactamase stability.</article-title><source>Antimicrob. Agents
Chemother.</source><volume>21</volume><year>1982</year><fpage>180</fpage><lpage>
187</lpage>.<pub-id pub-id-type="pmid">6979306</pub-id> </citation></ref><ref
id="B10"><label>10</label><citation><name><surname>Shungu</surname><given-names>D.
L.</given-names></name><name><surname>Cerami</surname><given-names>A.
T.</given-names></name><name><surname>Weinberg</surname><given-names>E.</given-names></name><name><surname>
Capizzi</surname><given-names>T.</given-names></name><name><surname>Gadebusch</surname><given-names>H.
H.</given-names></name><article-title>Tentative interpretive criteria for in vitro
antibacterial susceptibility testing with imipenem.</article-title><source>J. Clin.
Microbiol.</source><volume>23</volume><year>1986</year><fpage>421</fpage><lpage>
424</lpage>.<pub-id pub-id-type="pmid">3514655</pub-id>
</citation></ref><?mtl /hellip?>
</ref-list>
</back>
</article> 
